Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer

BACKGROUND: Endocrine therapy (ET) and ET-based regimens are the preferred first-line treatment options for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HR+/HER2– MBC), while chemotherapy (CT) is commonly used in clinical pract...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Yang, Zhang, Shaohua, Wang, Tao, Bian, Li, Yan, Min, Yin, Yongmei, Song, Yuhua, Wen, Yi, Li, Jianbin, Jiang, Zefei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278751/
https://www.ncbi.nlm.nih.gov/pubmed/37101355
http://dx.doi.org/10.1097/CM9.0000000000002676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278751/
https://www.ncbi.nlm.nih.gov/pubmed/37101355
http://dx.doi.org/10.1097/CM9.0000000000002676

Ejemplares similares